Results 361 to 370 of about 137,029 (384)
Some of the next articles are maybe not open access.

Infliximab in Psoriatic Arthritis

The Journal of Rheumatology Supplement, 2012
Tumor necrosis factor-α (TNF-α) plays a central role in the pathogenesis of psoriasis and psoriatic arthritis (PsA). Recently, 2 expert committees provided evidence-based recommendations for the treatment of PsA. Anti-TNF-α drugs are indicated in all forms of PsA resistant to traditional therapeutic approaches.
Olga Kaloudi   +4 more
openaire   +3 more sources

The Use of Infliximab in Dermatology

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 2007
Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis especially in psoriasis and psoriatic arthritis.
Demirtaşoǧlu, Melda, FETİL, EMEL
openaire   +6 more sources

Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study

Annals of Internal Medicine, 2018
Infliximab is an antitumor necrosis factor (TNF) monoclonal antibody approved for the treatment of Crohn disease (CD), ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis.
A. Meyer   +5 more
semanticscholar   +1 more source

Ocular Safety of Infliximab

Journal of Ocular Pharmacology and Therapeutics, 2011
Dear Editor: We read with interest the recent paper by Giansanti et al. on the intraocular safety of infliximab (Remicade ) in animal and cell culture models. Infliximab safety is an important factor as intraocular use of anti-Tumor Necrosis Factor (TNF)-a agents have been proposed as a potential therapeutic approach for patients with ocular ...
David G. Telander   +2 more
openaire   +3 more sources

Infliximab Treatment of Sarcoidosis

Annals of Pharmacotherapy, 2003
OBJECTIVE: To determine whether there is sufficient evidence in the literature to support the use of infliximab in the treatment of sarcoidosis. DATA SOURCES AND SELECTION: Literature was accessed through MEDLINE (1966–August 2002), OVID (2001–January 2003), and bibliographic searches. Additional databases were also searched.
openaire   +2 more sources

Infliximab

Annales de Dermatologie et de Vénéréologie, 2011
C, Goujon, H, Bachelez
openaire   +3 more sources

Infliximab and Golimumab

2014
Psoriasis and psoriatic arthritis are common chronic inflammatory disorders with substantial physical, financial and psychosocial burdens for patients. Biologic therapy for these conditions has been a major improvement in the therapeutic armamentarium. These drugs can maintain control of the disease, restore physical function and significantly improve ...
Robert E. Kalb, Cerrene Nicole Giordano
openaire   +2 more sources

Infliximab and Cogan’s syndrome

Clinical Otolaryngology, 2010
E. Beccastrini   +4 more
openaire   +4 more sources

Remicade (Infliximab)

Gastroenterology Nursing, 1998
openaire   +2 more sources

Home - About - Disclaimer - Privacy